biotheranostics breast cancer index

Release time ：Dec-18,2024

The Breast Cancer Index (BCI) is a biomarker test designed to evaluate the risk of recurrence and response to therapy in patients with breast cancer. By analyzing specific protein and gene expression patterns within tumor cells, it offers personalized treatment advice. The BCI assists physicians in identifying patients who might benefit from adjuvant chemotherapy and those who could be better suited to endocrine therapy.

Typically, the BCI score ranges from 0 to 100, with higher scores signifying a higher risk of recurrence. Patients classified as low risk (with scores below 25) may not require adjuvant chemotherapy, whereas those deemed high risk (with scores above 75) might need to contemplate more intensive treatment strategies. However, each patient's case is unique, and physicians must also take into account additional factors when devising treatment plans, such as the patient's age, tumor size and grade, lymph node status, and hormone receptor status.

Following a breast cancer diagnosis, it is crucial for patients to collaborate closely with their healthcare providers to understand their BCI score and select the most suitable treatment options based on medical advice. Additionally, adopting a healthy lifestyle, including a balanced diet, regular exercise, smoking cessation, and moderate alcohol consumption, can aid in reducing the risk of recurrence and enhancing the quality of life. Throughout the treatment journey, regular follow-ups and monitoring are essential to make timely adjustments to the treatment plan.